Harrison Barney
Royal Hallamshire Hospital, Sheffield, UK. harind@
Horm Res. 2007;68 Suppl 5:105-6. doi: 10.1159/000110590. Epub 2007 Dec 10.
All patients diagnosed with medullary thyroid carcinoma (MTC) should undergo RET mutation analysis to exclude familial disease - multiple endocrine neoplasia (MEN)-2A and -2B and familial medullary thyroid carcinoma (FMTC). In young patients at risk of genetically determined MTC, the key to a good outcome is an appropriate first operation, and this will depend upon the codon mutation, patient age, calcitonin level and disease extent at presentation. When MTC has already developed, a therapeutic intervention is required.
The thyroid, pituitary, adrenal, parathyroid and pancreatic components of MEN-1 and -2 require close collaboration of a specialist and experienced multidisciplinary team.
所有诊断为甲状腺髓样癌(MTC)的患者均应进行RET基因突变分析,以排除家族性疾病——多发性内分泌腺瘤病(MEN)-2A和-2B以及家族性甲状腺髓样癌(FMTC)。对于有遗传因素导致MTC风险的年轻患者,良好预后的关键在于进行恰当的首次手术,而这将取决于密码子突变、患者年龄、降钙素水平以及就诊时的疾病范围。当MTC已经发生时,需要进行治疗干预。
MEN-1和-2的甲状腺、垂体、肾上腺、甲状旁腺和胰腺组成部分需要专业且经验丰富的多学科团队密切协作。